London
10 °C
Manchester
Glasgow
9 °C
Dublin
8 °C
Belfast
Washington
Denver
7 °C
Atlanta
2 °C
Dallas
Houston Texas
New Orleans
El Paso
Phoenix
14 °C
Los Angeles
-6 °C
10 °C
-12 °C
-2 °C
Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP
NYSE - LSE
| RYCEF | -1.71% | 14.65 | $ | |
| RIO | 0.5% | 76.2 | $ | |
| RBGPF | 4.1% | 81 | $ | |
| GSK | -0.5% | 48.995 | $ | |
| SCS | 0.12% | 16.14 | $ | |
| AZN | -1.15% | 90.52 | $ | |
| NGG | -0.83% | 75.405 | $ | |
| RELX | -1.08% | 40.64 | $ | |
| CMSD | 0.04% | 23.375 | $ | |
| CMSC | 0.15% | 23.335 | $ | |
| VOD | -0.63% | 12.62 | $ | |
| BCE | -0.46% | 23.502 | $ | |
| BCC | 2.03% | 76.89 | $ | |
| JRI | -0.3% | 13.52 | $ | |
| BP | -4.18% | 33.836 | $ | |
| BTI | -0.45% | 57.48 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
K.Morrison--SMC
